Gut barrier dysfunction and endotoxemia in heart failure: A dangerous connubium?
Level 5 - mechanism / opinion, no new human data
Narrative review summarizing mechanisms and clinical concepts without systematic search methodology
PubMed 37301317 · doi:10.1016/j.ahj.2023.06.002
What was done
This narrative review synthesized experimental and clinical evidence addressing the relationship between gut microbiota dysbiosis, gut barrier impairment, bacterial translocation leading to endotoxemia, heart failure progression, and potential therapeutic countermeasures.
What was found
The abstract reports no numerical values or effect sizes. It notes that elevated circulating lipopolysaccharide (LPS) is present across cardiometabolic conditions (diabetes, obesity, nonalcoholic fatty liver disease, myocardial infarction, atrial fibrillation) and outlines that LPS interaction with Toll-like receptor 4 (TLR4) prompts proinflammatory cytokine production and procoagulant effects, conceptually associating gut-derived endotoxemia with heart failure worsening.
Why it matters
The paper outlines mechanistic pathways linking gut permeability and endotoxemia to systemic inflammation in heart failure, highlighting potential targets for adjunctive therapeutic strategies.
Limits
This is a narrative review with no original data, systematic search protocol, or meta-analytic pooling reported in the abstract. Specific clinical endpoints, quantitative effect magnitudes, and verified therapeutic outcomes are not provided.
Cited by
- supports LPS is the outer covering of gram-negative bacteria that reside in the gut and is an initiator of inflammation.